^
    1d
    Chidamide, Venetoclax, Azacitidine, and Homoharringtonine for High-risk Fit AML (clinicaltrials.gov)
    P2, N=46, Not yet recruiting, Dongguan People's Hospital
    New P2 trial
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • Epidaza (chidamide) • Synribo (omacetaxine mepesuccinate)
    1d
    Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Ninlaro (ixazomib) • Hemady (dexamethasone tablets)
    1d
    Viale-a: A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy (clinicaltrials.gov)
    P3, N=443, Active, not recruiting, AbbVie | Completed --> Active, not recruiting | Trial completion date: Nov 2025 --> Jun 2026
    Enrollment closed • Trial completion date
    |
    Venclexta (venetoclax) • azacitidine
    1d
    Ph- ALL-2026: Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial (clinicaltrials.gov)
    P2, N=32, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    |
    CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    Venclexta (venetoclax) • cytarabine • cyclophosphamide • Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • vincristine • prednisone • mercaptopurine
    1d
    Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=58, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • CD4 (CD4 Molecule)
    |
    TP53 mutation • Chr del(17p) • TP53 wild-type
    |
    Venclexta (venetoclax) • decitabine • navtemadlin (KRT-232)
    1d
    The All-Oral Combination of Revumenib, Decitabine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (SAVE). (PubMed, J Clin Oncol)
    This combination was associated with high response rates and durable remissions, with an acceptable safety, in heavily pretreated patients with AML harboring alterations susceptible to menin inhibition.
    Journal • IO biomarker
    |
    NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A) • NUP98 (Nucleoporin 98 And 96 Precursor 2)
    |
    NPM1 mutation • KMT2A rearrangement
    |
    Venclexta (venetoclax) • Revuforj (revumenib) • Inqovi (decitabine/cedazuridine)
    1d
    Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=36, Completed, University of Colorado, Denver | Active, not recruiting --> Completed | Trial completion date: Jun 2027 --> Feb 2026
    Trial completion • Trial completion date
    |
    Venclexta (venetoclax) • azacitidine
    1d
    Efficacy analysis of CAR-T cells against CD123-positive malignant tumors and exploration of the feasibility of combination therapy with venetoclax. (PubMed, Ann Hematol)
    Multi-omics analysis combining transcriptomic and metabolomic sequencing identified distinct alterations in key metabolic pathways between CD123 CAR-T cells and V-CD123 CAR-T cells. We propose that low-dose venetoclax combined with CD123 CAR-T cells enhances cytotoxicity, which may be attributed to metabolic optimization in CAR-T cells.
    Journal
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • GLI2 (GLI Family Zinc Finger 2)
    |
    Venclexta (venetoclax)
    2d
    VA-CAG Two-Week vs. Three-Week Regimen for Induction Remission in Newly Diagnosed Acute Myeloid Leukemia. (clinicaltrials.gov)
    P2, N=110, Not yet recruiting, Hematology department of the 920th hospital
    New P2 trial
    |
    Venclexta (venetoclax) • cytarabine • azacitidine
    2d
    Radiation induces senescence in lymphatic endothelial cells (LECs) and murine tail lymphedema tissue, contributing to lymphedema progression. (PubMed, Cell Death Dis)
    Treatment with the senolytic agent venetoclax (VCX), a BCL-2 inhibitor, selectively killed RT-induced senescent LECs and reduced swelling in the RT-induced tail lymphedema model. This suggests that RT contributes to CRL, at least in part, by inducing cellular senescence.
    Preclinical • Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • FLT4 (Fms-related tyrosine kinase 4) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    Venclexta (venetoclax)
    3d
    HOVON 182 CLL: HO182 CLL: Treatment of patients with chronic lymphocytic leukemia (CLL) with 6 cycles of rituximab in combination with 6 or 26 cycles of venetoclax upon recurrence of the disease after previous treatment (2025-524283-38-00)
    P2/3, N=456, Not yet recruiting, Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
    New P2/3 trial
    |
    TP53 (Tumor protein P53) • IGH (Immunoglobulin Heavy Locus)
    |
    TP53 mutation • IGH mutation
    |
    Venclexta (venetoclax) • Rituxan (rituximab)
    3d
    APHP251246: ACTIVATE - Phase 1 Clinical Trial evaluating the combination of Actinomycin D and venetoclax in patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) (2025-524728-22-01)
    P1/2, N=36, Not yet recruiting, Assistance Publique Hopitaux De Paris
    New P1/2 trial
    |
    Venclexta (venetoclax) • dactinomycin